AAAAAA
Results:
1-14
|
Results: 14
Authors:
Martin, DS
Spriggs, D
Koutcher, JA
Citation: Ds. Martin et al., A concomitant ATP-depleting strategy markedly enhances anticancer agent activity, APOPTOSIS, 6(1-2), 2001, pp. 125-131
Authors:
Hensley, ML
Lebeau, D
Leon, LF
Venkatraman, E
Waltzman, R
Sabbatini, P
Almadrones, L
Chi, D
Spriggs, D
Citation: Ml. Hensley et al., Identification of risk factors for requiring transfusion during front-linechemotherapy for ovarian cancer, GYNECOL ONC, 81(3), 2001, pp. 485-489
Authors:
Markman, M
Spriggs, D
Burger, RA
Carson, LF
Lentz, SS
Gallion, H
Citation: M. Markman et al., Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: A Gynecologic Oncology Group study, GYNECOL ONC, 80(3), 2001, pp. 359-363
Authors:
Acosta, OM
Albus, KE
Reynolds, MW
Spriggs, D
Weist, MD
Citation: Om. Acosta et al., Assessing the status of research on violence-related problems among youth, J CLIN CHIL, 30(2), 2001, pp. 152-160
Authors:
Harper, RM
Bandler, R
Spriggs, D
Alger, JR
Citation: Rm. Harper et al., Lateralized and widespread brain activation during transient blood pressure elevation revealed by magnetic resonance imaging, J COMP NEUR, 417(2), 2000, pp. 195-204
Authors:
Sabbatini, PJ
Kudryashov, V
Ragupathi, G
Danishefsky, SJ
Livingston, PO
Bornmann, W
Spassova, M
Zatorski, A
Spriggs, D
Aghajanian, C
Soignet, S
Peyton, M
O'Flaherty, C
Curtin, J
Lloyd, KO
Citation: Pj. Sabbatini et al., Immunization of ovarian cancer patients with a synthetic Lewis(Y)-protein conjugate vaccine: A phase 1 trial, INT J CANC, 87(1), 2000, pp. 79-85
Authors:
Robins, HI
Katschinski, DM
Longo, W
Grosen, E
Wilding, G
Gillis, W
Kraemer, C
Tiggelaar, CL
Stewart, JA
Spriggs, D
Arzoomanian, RZ
Feierabend, C
Alberti, D
Morgan, K
Simon, K
d'Oleire, F
Citation: Hi. Robins et al., A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees Cwhole-body hyperthermia, CANC CHEMOT, 43(5), 1999, pp. 409-414
Authors:
Parker, JM
Alger, JR
Woo, MA
Spriggs, D
Harper, RM
Citation: Jm. Parker et al., Acquisition of electrophysiologic signals during magnetic resonance imaging, SLEEP, 22(8), 1999, pp. 1125-1126
Authors:
Hensley, ML
Sabbatini, P
Spriggs, D
Citation: Ml. Hensley et al., Implementation of disease management guidelines in patients with advanced ovarian cancer, SEMIN ONCOL, 26(1), 1999, pp. 46-51
Authors:
Husain, A
Spriggs, D
Barakat, R
Citation: A. Husain et al., Gastrointestinal toxicity is not a major complication of standard dose paclitaxel therapy, GYNECOL ONC, 74(1), 1999, pp. 153-154
Authors:
Husain, A
Sabbatini, P
Spriggs, D
Fennelly, D
Aghajanian, C
Barakat, R
Curtin, J
Venkatraman, E
Hoskins, W
Markman, M
Citation: A. Husain et al., Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer, GYNECOL ONC, 73(1), 1999, pp. 96-101
Authors:
Killeen, K
Spriggs, D
Mekalanos, J
Citation: K. Killeen et al., Bacterial mucosal vaccines: Vibrio cholerae as a live attenuated vaccine/vector paradigm, CURR T MICR, 236, 1999, pp. 237-254
Authors:
Spriggs, D
Busch, S
Citation: D. Spriggs et S. Busch, Organised management teams for stroke - What are they and what are their advantages?, CNS DRUGS, 10(6), 1998, pp. 399-404
Authors:
Saltz, LB
Spriggs, D
Schaaf, LJ
Schwartz, GK
Ilson, D
Kemeny, N
Kanowitz, J
Steger, C
Eng, M
Albanese, P
Semple, D
Hanover, CK
Elfring, GL
Miller, LL
Kelsen, D
Citation: Lb. Saltz et al., Phase I clinical and pharmacologic study of weekly cisplatin combined withweekly irinotecan in patients with advanced solid tumors, J CL ONCOL, 16(12), 1998, pp. 3858-3865
Risultati:
1-14
|